AI-based liquid biopsy technology promises early detection of cancer recurrence

FHS
June 14, 2024
1:15 pm

An artificial intelligence-powered method for detecting tumor DNA in blood has shown unprecedented sensitivity in predicting cancer recurrence, in a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian, the New York Genome Center (NYGC) and Memorial Sloan Kettering Cancer Center (MSK).

GC Biopharma, Eubiologics enter deal to produce cholera vaccine

The companies will jointly manufacture the cholera vaccine from the first half of 2024. Credit: Andrey_Popov / Shutterstock.com. South Korean biopharmaceutical firm GC Biopharma has

August 28, 2023

Generative AI Tracker: A guide to the health systems and companies driving adoption

Health care leaders and technology companies are investing heavily in large language models, a powerful class of deep learning models that are trained on vast

September 5, 2023

Amgen and Horizon call FTC’s attempt to block $28B merger unconstitutional in counterclaims

Amgen and Horizon filed counterclaims against the FTC, alleging the agency’s attempt to block their nearly $28 billion merger “runs roughshod” over provisions of the

July 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.